Familial FSGS

Advances in Chronic Kidney Disease

Volumn 21, Issue 5, 2014, Pages 422-425

  Pollak, Martin R ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

FSGS; Genetic

Indexed keywords

APOL1 PROTEIN, HUMAN; APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN;

BLACK PERSON; FOCAL GLOMERULOSCLEROSIS; GENETIC PREDISPOSITION; GENETICS; HUMAN; MUTATION;

AFRICAN CONTINENTAL ANCESTRY GROUP; APOLIPOPROTEINS; GENETIC PREDISPOSITION TO DISEASE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; LIPOPROTEINS, HDL; MUTATION;

EID: 84906725278     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.06.001     Document Type: Review

References (54)

1. Brown E.J., Schlondorff J.S., Becker D.J., et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet 2010, 42(1):72-76.
2. Gbadegesin R.A., Lavin P.J., Hall G., et al. Inverted formin 2 mutations with variable expression in patients with sporadic and hereditary focal and segmental glomerulosclerosis. Kidney Int 2012, 81(1):94-99.
3. Boyer O., Benoit G., Gribouval O., et al. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol 2011, 22(2):239-245.
4. Barua M., Brown E.J., Charoonratana V.T., Genovese G., Sun H., Pollak M.R. Mutations in the INF2 gene account for a significant proportion of familial but not sporadic focal and segmental glomerulosclerosis. Kidney Int 2013, 83(2):316-322.
5. Boyer O., Nevo F., Plaisier E., et al. INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. N Engl J Med 2011, 365(25):2377-2388.
6. Kaplan J.M., Kim S.H., North K.N., et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000, 24(3):251-256.
7. Winn M.P., Conlon P.J., Lynn K.L., et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005, 308(5729):1801-1804.
8. Weins A., Schlondorff J.S., Nakamura F., et al. Disease-associated mutant alpha-actinin-4 reveals a mechanism for regulating its F-actin-binding affinity. Proc Natl Acad Sci U S A 2007, 104(41):16080-16085.
9. Reiser J., Polu K.R., Moller C.C., et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 2005, 37(7):739-744.
10. Tian D., Jacobo S.M., Billing D., et al. Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels. Sci Signal 2010, 3(145):ra77.
11. Schlondorff J., Del Camino D., Carrasquillo R., Lacey V., Pollak M.R. TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription. Am J Physiol Cell Physiol 2009, 296(3):C558-C569.
12. Chiluiza D., Krishna S., Schumacher V.A., Schlondorff J. Gain-of-function mutations in transient receptor potential C6 (TRPC6) activate extracellular signal-regulated kinases 1/2 (ERK1/2). J Biol Chem 2013, 288(25):18407-18420.
13. Akilesh S., Suleiman H., Yu H., et al. Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J Clin Invest 2011, 121(10):4127-4137.
14. Kim J.M., Wu H., Green G., et al. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 2003, 300(5623):1298-1300.
15. Lowik M.M., Groenen P.J., Pronk I., et al. Focal segmental glomerulosclerosis in a patient homozygous for a CD2AP mutation. Kidney Int 2007, 72(10):1198-1203.
16. Kreidberg J.A., Hartwig S. Wilms' tumor-1: a riddle wrapped in a mystery, inside a kidney. Kidney Int 2008, 74(4):411-412.
17. Pelletier J., Bruening W., Li F.P., Haber D.A., Glaser T., Housman D.E. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature 1991, 353(6343):431-434.
18. Barbaux S., Niaudet P., Gubler M.C., et al. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 1997, 17(4):467-470.
19. Ruf R.G., Schultheiss M., Lichtenberger A., et al. Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. Kidney Int 2004, 66(2):564-570.
20. Mucha B., Ozaltin F., Hinkes B.G., et al. Mutations in the Wilms' tumor 1 gene cause isolated steroid resistant nephrotic syndrome and occur in exons 8 and 9. Pediatr Res 2006, 59(2):325-331.
21. Niaudet P., Gubler M.C. WT1 and glomerular diseases. Pediatr Nephrol 2006, 21(11):1653-1660.
22. Jeanpierre C., Denamur E., Henry I., et al. Identification of constitutional WT1 mutations, in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/phenotype correlations by use of a computerized mutation database. Am J Hum Genet 1998, 62(4):824-833.
23. Kestila M., Lenkkeri U., Mannikko M., et al. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol Cell 1998, 1(4):575-582.
24. Huber T.B., Benzing T. The slit diaphragm: a signaling platform to regulate podocyte function. Curr Opin Nephrol Hypertens 2005, 14(3):211-216.
25. Philippe A., Nevo F., Esquivel E.L., et al. Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2008, 19(10):1871-1878.
26. Santin S., Garcia-Maset R., Ruiz P., et al. Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis. Kidney Int 2009, 76(12):1268-1276.
27. Boute N., Gribouval O., Roselli S., et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000, 24(4):349-354.
28. Hinkes B.G., Mucha B., Vlangos C.N., et al. Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 2007, 119(4):e907-e919.
29. Tsukaguchi H., Sudhakar A., Le T.C., et al. NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest 2002, 110(11):1659-1666.
30. Benoit G., Machuca E., Nevo F., Gribouval O., Lepage D., Antignac C. Analysis of recessive CD2AP and ACTN4 mutations in steroid-resistant nephrotic syndrome. Pediatr Nephrol 2010, 25(3):445-451.
31. Hinkes B., Vlangos C., Heeringa S., et al. Specific podocin mutations correlate with age of onset in steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2008, 19(2):365-371.
32. Weber S., Gribouval O., Esquivel E.L., et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 2004, 66(2):571-579.
33. Tonna S.J., Needham A., Polu K., et al. NPHS2 variation in focal and segmental glomerulosclerosis. BMC Nephrol 2008, 9:13.
34. Machuca E., Hummel A., Nevo F., et al. Clinical and epidemiological assessment of steroid-resistant nephrotic syndrome associated with the NPHS2 R229Q variant. Kidney Int 2009, 75(7):727-735.
35. Santin S., Tazon-Vega B., Silva I., et al. Clinical value of NPHS2 analysis in early- and adult-onset steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2011, 6(2):344-354.
36. Ruf R.G., Lichtenberger A., Karle S.M., et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004, 15(3):722-732.
37. Jungraithmayr T.C., Hofer K., Cochat P., et al. Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation. J Am Soc Nephrol 2011, 22(3):579-585.
38. Schwarz K., Simons M., Reiser J., et al. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest 2001, 108(11):1621-1629.
39. Roselli S., Gribouval O., Boute N., et al. Podocin localizes in the kidney to the slit diaphragm area. Am J Pathol 2002, 160(1):131-139.
40. Huber T.B., Kottgen M., Schilling B., Walz G., Benzing T. Interaction with podocin facilitates nephrin signaling. J Biol Chem 2001, 276(45):41543-41546.
41. Huber T.B., Simons M., Hartleben B., et al. Molecular basis of the functional podocin-nephrin complex: mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft microdomains. Hum Mol Genet 2003, 12(24):3397-3405.
42. Hinkes B., Wiggins R.C., Gbadegesin R., et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 2006, 38(12):1397-1405.
43. Ovunc B., Otto E.A., Vega-Warner V., et al. Exome sequencing reveals cubilin mutation as a single-gene cause of proteinuria. J Am Soc Nephrol 2011, 22(10):1815-1820.
44. Mele C., Iatropoulos P., Donadelli R., et al. MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med 2011, 365(4):295-306.
45. Sanna-Cherchi S., Burgess K.E., Nees S.N., et al. Exome sequencing identified MYO1E and NEIL1 as candidate genes for human autosomal recessive steroid-resistant nephrotic syndrome. Kidney Int 2011, 80(4):389-396.
46. Gee H.Y., Saisawat P., Ashraf S., et al. ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. J Clin Invest 2013, 123(8):3243-3253.
47. Gupta I.R., Baldwin C., Auguste D., et al. ARHGDIA: a novel gene implicated in nephrotic syndrome. J Med Genet 2013, 50(5):330-338.
48. Ashraf S., Gee H.Y., Woerner S., et al. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest 2013, 123(12):5179-5189.
49. Kopp J.B., Smith M.W., Nelson G.W., et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40(10):1175-1184.
50. Kao W.H., Klag M.J., Meoni L.A., et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008, 40(10):1185-1192.
51. Genovese G., Friedman D.J., Ross M.D., et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010, 329(5993):841-845.
52. Tzur S., Rosset S., Shemer R., et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010, 128(3):345-350.
53. Kopp J.B., Nelson G.W., Sampath K., et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011, 22(11):2129-2137.
54. Friedman D.J., Kozlitina J., Genovese G., Jog P., Pollak M.R. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol 2011, 22(11):2098-2105.